Quince Therapeutics, Inc.QNCXNASDAQ
LOADING
|||
QNCX Revenue Growth (YoY Quarterly)•+0.00%
SAPRO
Growth Metrics
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Gross Profit Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +19.66% | +5.59% | +2.16% | +8.33% | +24.99% |
| Weighted Average Shares Diluted Growth | +19.66% | +5.59% | +2.16% | +8.33% | +24.99% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | +99.00% | -11.18% | -5.66% | +2.90% | -100.00% |
| Inventory Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Asset Growth | +48.17% | -36.47% | -32.77% | -13.07% | -13.14% |
| Book Value per Share Growth | -54.83% | -66.44% | -75.48% | -76.93% | -98.11% |
| Debt Growth | +25227.87% | +7.22% | +11.78% | +21.60% | +16.46% |
| R&D Expense Growth | +243.54% | +69.63% | +120.02% | +58.02% | +64.42% |
| SG&A Expenses Growth | -22.15% | -7.32% | -3.66% | -28.82% | -10.61% |
1 / 4